Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| VivoSense | 2023 | Grant | Undisclosed | Newport Coast |
| GeneDx | 2023 | Post-IPO Equity | Undisclosed | Stamford |
| Athira Pharma | 2025 | Post-IPO Equity | Undisclosed | Seattle |
| Mythic Therapeutics | 2021 | Series B | Undisclosed | Waltham |
| Contineum Therapeutics | 2025 | Post-IPO Equity | Undisclosed | San Diego |
| BridgeBio | 2026 | Post-IPO Debt | Undisclosed | Palo Alto |
| Thrive Earlier Detection | 2023 | Venture - Series Unknown | Undisclosed | Cambridge |
| Sermonix Pharmaceuticals | 2021 | Series A | Undisclosed | Columbus |
| Alector | 2024 | Post-IPO Debt | Undisclosed | San Francisco |
| TELA Bio | 2025 | Post-IPO Debt | Undisclosed | Malvern |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | VivoSense | Grant | Undisclosed | Newport Coast, United States |
| 52 | GeneDx | Post-IPO Equity | Undisclosed | Stamford, United States |
| 53 | Athira Pharma | Post-IPO Equity | Undisclosed | Seattle, United States |
| 54 | Mythic Therapeutics | Series B | Undisclosed | Waltham, United States |
| 55 | Contineum Therapeutics | Post-IPO Equity | Undisclosed | San Diego, United States |
| 56 | BridgeBio | Post-IPO Debt | Undisclosed | Palo Alto, United States |
| 57 | Thrive Earlier Detection | Venture - Series Unknown | Undisclosed | Cambridge, United States |
| 58 | Sermonix Pharmaceuticals | Series A | Undisclosed | Columbus, United States |
| 59 | Alector | Post-IPO Debt | Undisclosed | San Francisco, United States |
| 60 | TELA Bio | Post-IPO Debt | Undisclosed | Malvern, United States |
VivoSense is an advancing clinical research with wearable sensor solutions.
GeneDx uses artificial intelligence and machine learning to analyze patient data to provide insights to transform the practice of medicine.
Athira Pharma is a clinical stage drug development company that specializes in biotechnology and pharmaceutical.
Mythic Therapeutics is a biotechnology company focused on a new generation of groundbreaking cancer therapeutics.
Contineum Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases.
BridgeBio focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.
Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.
Sermonix Pharmaceuticals is an Ohio LLC specialty pharmaceutical.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.
TELA Bio is a life science company that specializes in soft tissue reconstruction.
Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.
Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.
Axonis Therapeutics is a neuro-focused biotechnology company that focuses on the development of novel neuromedicines.
Adagio Medical is engaged in the research and development of treatments for cardiovascular diseases.
Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.
Alto Neuroscience is a clinical-stage biopharmaceutical company that creates precision medicines through its AI-driven biomarker platform.
Outlook Therapeutics is a biopharmaceutical company that develops ophthalmic formulations.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Beam Therapeutics is a biotechnology company developing precision genetic medicines through the use of base editing technology.
Talkiatry provides virtual mental healthcare services covered by insurance, connecting patients with licensed psychiatrists.
Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.
Nautilus Biotechnology is a life sciences company that develops a platform for analyzing and quantifying the human proteome.
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Crescent Biopharma is a biotechnology firm focused on developing novel precision-engineered medicines.
Hyperfine makes MRI accessible to every patient regardless of income or resources.
Perceptive Advisors has invested in 168 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Perceptive Advisors's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 26 different industry categories.
Among tracked funding rounds, Solid Biosciences received $240.0M in a Post Ipo Equity round. Perceptive Advisors's total known invested capital is $9.5B.
Perceptive Advisors's average investment size is $101.5M across its portfolio of 168 companies.
Recent Perceptive Advisors portfolio additions include VivoSense, GeneDx, Athira Pharma, Mythic Therapeutics, Contineum Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors